Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel Capabilities
Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel Capabilities
Project is part of the U.S. Department of Defense's BioMADE initiative to support U.S. bioindustrial manufacturing innovations and workforce development
该项目是美国国防部BioMADE计划的一部分,旨在支持美国生物工业制造创新和劳动力发展。
Monrovia, CA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc., (NASDAQ: IZTC) ("Invizyne"), a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, announced it was awarded a $2 million project to enable enzyme production for cell-free biomanufacturing of sustainable aviation fuel (SAF).
加利福尼亚州蒙罗维亚,2024年11月19日(全球新闻稿)-- 今天,Invizyne Technologies, Inc.(纳斯达克:IZTC)("Invizyne"),一家领先的细胞自由酶生物制造系统设计公司,旨在生产对日常生活重要的分子和化学品,宣布获得一项200万美元的项目,以实现可持续航空燃料(SAF)的细胞自由生物制造中酶的生产。
The project is a cost share grant from the U.S. Department of Defense's BioMADE initiative, in partnership with the University of Georgia. It is one of 17 BioMADE projects announced on October 30, 2024, to drive the scale-up and commercialization of American biomanufactured products.
该项目是美国国防部BioMADE计划的一项成本分摊资助,与乔治亚州大学合作。它是2024年10月30日宣布的17个BioMADE项目之一,旨在推动美国生物制造产品的规模化和商业化。
"The next five to ten years will determine the global leader of the bioeconomy. At BioMADE, we believe the U.S. is uniquely positioned to seize this opportunity," said Dr. Douglas Friedman, Chief Executive Officer at BioMADE. "We are proud to support these member-driven projects that will translate our country's rich history of biotechnology innovation into manufacturing leadership. All Americans will benefit from investments in America's bioindustrial manufacturing future."
“未来五到十年将判断生物经济的全球领导者。在BioMADE,我们相信美国在抓住这一机遇方面具有独特优势,”BioMADE首席执行官道格拉斯·弗里德曼(Dr. Douglas Friedman)说。“我们为支持这些以成员为驱动的项目感到自豪,这些项目将我们的国家在生物技术创新方面的丰富历史转化为制造业领导地位。所有美国人都将从对美国生物工业制造未来的投资中受益。”
Novel Cell-Free Approach to Address $27.5 Billion Market
Prior to the BioMADE grant, Invizyne was awarded a total of $5.85 million in grants from the Bioenergy Technologies Office (BETO) within the U.S. Department of Energy's (DOE's) Office of Energy Efficiency and Renewable Energy (EERE) to develop its novel cell-free approach for isobutanol production.
新型无细胞方法应对275亿美元的市场
在获得BioMADE资助之前,Invizyne获得了来自美国能源部能源效率与可再生能源办公室(EERE)下的生物能源技术办公室(BETO)共计585万美元的资助,用于开发其新型无细胞异丁醇生产方法。
Isobutanol is a commodity chemical that can replace conventional petroleum-based fuels like gasoline and serves as a precursor to SAF. The global SAF market is expected to grow at a compound annual rate of 52.2% to reach $27.4 billion by 2032, according to Acumen Research and Consulting.
异丁醇是一种商品化学品,可以替代传统的石油基燃料,如汽油,并作为可持续航空燃料的前体。根据Acumen Research and Consulting,全球可持续航空燃料市场预计将以52.2%的复合年增长率增长,到2032年达到274亿。
Project Details
The latest grant from BioMADE will be used to take the next step toward cell-free biomanufacturing of isobutanol. Specifically, it will be used to develop an enzyme production and processing pipeline and deploy Invizyne's technology in 100L pilot-scale facilities.
项目详情
BioMADE最新的拨款将用于向细胞无生物制造异丁醇的下一步迈进。具体来说,拨款将用于开发酶的生产和处理流程,并在100升试点规模的设施中部署Invizyne的科技。
"This initiative could indeed mark the beginning of a new era in sustainable biofuel production, bringing us closer to a greener, more efficient future. That's because at its heart, this project seeks to mature the Technology Readiness Level of our cell-free enzyme approach, enabling the project participants to convert renewable sugars into isobutanol at scale," said Paul Opgenorth, PhD, Co-Founder & VP of Development at Invizyne.
“这一倡议确实可以标志着可持续生物燃料生产新时代的开始,使我们更接近一个更绿色、更高效的未来。这是因为在其核心,这个项目旨在提升我们无细胞酶方法的技术准备水平,使项目参与者能够在大规模生产中将可再生糖转化为异丁醇,”Invizyne的联合创始人兼开发副总裁Paul Opgenorth博士表示。
Broader Vision and Impact
"While the BioMADE project will play a pivotal role in validating the technical and economic feasibility of cell-free isobutanol production, it's also important to understand that our vision at Invizyne extends beyond biofuel applications," said Michael Heltzen, CEO of Invizyne. "We see this project as establishing a framework for expanding Invizyne's cell-free approach into various industrial processes, too. Now that we have completed our IPO and we are able to continue to mature our technology, I fully believe we can become the leader in next generation biomanufacturing and dramatically reduce greenhouse gas emissions and foster a shift toward renewable solutions in the process."
更广泛的愿景和影响
“虽然BioMADE项目在验证无细胞异丁醇生产的技术和经济可行性方面将发挥关键作用,但了解我们在Invizyne的愿景超越生物燃料应用同样重要,”Invizyne首席执行官Michael Heltzen表示。“我们将这个项目视为扩展Invizyne无细胞方法到各种工业流程的框架。现在我们的首次公开募股(IPO)已经完成,我们能够继续成熟我们的技术,我完全相信我们可以成为下一代生物制造的领导者,并在此过程中显著减少温室气体排放,促进向可再生解决方案的转变。”
About BioMADE
By supporting the scale-up of bioindustrial manufacturing technology from research labs to commercial production, BioMADE and its network of nearly 300 members across 37 states are strengthening American competitiveness, securing the U.S. supply chain, reshoring manufacturing jobs, supporting rural development and domestic agriculture, and producing more sustainable products untethered from reliance on petroleum. BioMADE is building a diverse and globally competitive STEM workforce, preparing American workers to fill new jobs throughout the U.S. bioindustrial manufacturing ecosystem, including BioMADE's national infrastructure network of pilot-scale facilities. BioMADE was catalyzed by the U.S. Department of Defense and is a proud member of Manufacturing USA. Read about the new projects below and learn more about BioMADE by visiting biomade.org
关于BioMADE
通过支持生物工业制造技术从研究实验室到商业生产的规模化,BioMADE及其在37个州的近300名成员网络正在增强美国的竞争力,保障美国的供应链,恢复制造业岗位,支持农村发展和国内农业,并生产更多与石油无关的可持续产品。BioMADE正在建立一个多元化且具有全球竞争力的STEm劳动力,为美国工人准备填补美国生物工业制造生态系统中新的职位,包括BioMADE的国家基础设施网络的试点规模设施。BioMADE受到美国国防部的推动,并自豪地成为Manufacturing USA的一员。阅读下面的新项目,并通过访问biomade.org了解更多关于BioMADE的信息。
About Invizyne
Invizyne Technologies, Inc. is a cell-free enzyme-based biomanufacturing technology company headquartered in Monrovia, California. Invizyne is redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals, such as Active Pharmaceutical Ingredients (APIs), biofuels, food flavors, fragrances, cosmetics, etc. Management of Invizyne believes that its biomanufacturing platform, known as SimplePath, will be a significant alternative to the current methods of chemical compound production, which are generally chemical synthesis, natural extraction, and synthetic biology. The objective for the SimplePath platform is to enable the efficient production of a diverse range of chemicals otherwise impossible to make, or very expensive to make. The SimplePath platform not only can maximize the value of these resources but also can contribute to the development of novel and renewable chemical compounds that hold the potential to open new markets and business opportunities.
关于Invizyne
Invizyne Technologies,Inc.是一家总部位于加利福尼亚州蒙罗维亚的无细胞酶基生物制造技术公司。Invizyne正在通过利用无细胞、多步酶基系统有效地将天然或可再生资源转化为备受追捧的生化产品(例如活性药用成分(API)、生物燃料、食品调味料、香精、化妆品等)来重新定义生物制造。Invizyne的管理团队认为,其生物制造平台SimplePath将成为目前化合物生产的重要替代方法,通常包括化学合成、天然提取和合成生物学。SimplePath平台的目标是实现有效生产各种否则难以制造或成本高昂的化学品。SimplePath平台不仅能最大程度地价值化这些资源,还能促进新型可再生化合物的开发,从而有望开拓新的市场和业务机遇。
For more information, please visit
更多信息,请访问:
Forward-Looking Statements
This press release contains "forward-looking statements." These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "aim", "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," "shall" and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements.
前瞻性声明
本新闻稿包含“前瞻性声明”。这些前瞻性声明是在首次发布之日作出的,基于当前的预期、估计、预测和 projections,以及管理层的信念和假设。像“目标”、“期望”、“预期”、“应该”、“相信”、“希望”、“瞄准”、“项目”、“目标”、“估计”、“潜力”、“预测”、“可能”、“将”、“可能”、“能够”、“打算”、“应”等词及其变体或这些词的否定形式和类似表达方式旨在识别这些前瞻性声明。
Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Invizyne's control. Invizyne's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors. The forward-looking statements included in this press release represent Invizyne's views as of the date of this press release. Invizyne anticipates that subsequent events and developments will cause its views to change. Invizyne undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Invizyne's views as of any date subsequent to the date of this press release.
前瞻性声明会受到许多涉及Invizyne无法控制的因素或环境的风险和不确定性的影响。 由于多种因素,Invizyne的实际结果可能与前瞻性声明中陈述或暗示的结果大不相同。 本新闻稿中包含的前瞻性声明代表Invizyne在本新闻稿发布日期的观点。 Invizyne预计随后的事件和发展将导致其观点发生变化。 Invizyne不打算也没有义务更新或修订任何前瞻性声明,无论是基于新信息、未来事件或其他原因。 不应依赖这些前瞻性声明作为代表Invizyne在本新闻稿发布日期后的任何日期观点。
Media contacts:
Lasse Görlitz, VP of Communications
(858) 319-7135
press@invizyne.com
媒体联系人:
Lasse Görlitz, 通信-半导体副总裁
(858) 319-7135
press@invizyne.com
Investor Relations Contact:
IR@invizyne.com
投资者关系联系方式:
IR@invizyne.com